[1] Siegel RL, Miller KD, Jemal A.Cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(1): 7-30.
[2] Pfister D, Spencer S, Adelstein D, et al. NCCN clinical practice guidelines in oncology (NCCN Guidelines®) for head and neck cancers. Version 2.2018. Fort Washington: National Comprehensive Cancer Network (NCCN) [DB/OL]. 2018. https://www.nccn.org/professionals/physician_gls/default.aspx.
[3] 中国临床肿瘤学会指南工作委员会.头颈部肿瘤诊疗指南2018.V1[DB/OL].中国临床肿瘤学会(CSCO).2018. http://www.csco.org.cn/.
[4] 曹雨庵, 郭伟. 我国口腔鳞癌的治疗现状[J]. 实用肿瘤杂志, 2012, 27(2): 109-112.
[5] Ballesta A, Innominato PF, Dallmann R, et al.Systems chronotherapeutics[J]. Pharmacol Rev, 2017, 69(2): 161-199.
[6] Ortiz-Tudela E, Innominato PF, Rol MA, et al.Relevance of internal time and circadian robustness for cancer patients[J]. BMC Cancer, 2016, 16: 285.
[7] Ozturk N, Ozturk D, Kavakli IH, et al.Molecular aspects of circadian pharmacology and relevance for cancer chronotherapy[J]. Int J Mol Sci, 2017, 18(10) : E2168.
[8] FitzGerald GA. Circadian rhythms.Temporal targets of drug action[J]. Science, 2014, 346(6212): 921-922.
[9] Sehgal A.Physiology flies with time[J]. Cell, 2017, 171(6):1232-1235.
[10] Turek FW.Circadian clocks: Not your grandfather's clock[J]. Science, 2016, 354(6315): 992-993.
[11] Innominato PF, Roche VP, Palesh OG, et al.The circadian timing system in clinical oncology[J]. Ann Med, 2014, 46(4): 191-207.
[12] Innominato PF, Lévi FA, Bjarnason GA.Chronotherapy and the molecular clock: Clinical implications in oncology[J]. Adv Drug Deliv Rev, 2010, 62(9-10): 979-1001.
[13] Ortiz-Tudela E, Mteyrek A, Ballesta A, et al.Cancer chronotherapeutics: experimental, theoretical, and clinical aspects[J]. Handb Exp Pharmacol, 2013, (217): 261-288.
[14] Lévi F, Okyar A, Dulong S, at el. Circadian timing in cancer treatments[J]. Annu Rev Pharmacol Toxicol, 2010, 50: 377-421.
[15] Sancar A, Lindsey-Boltz LA, Gaddameedhi S, at el. Circadian clock, cancer, and chemotherapy[J]. Biochemistry, 2015, 54(2): 110-123.
[16] 杨凯, 陈睿, 喻秀丽. 口腔癌时辰化疗[J]. 实用口腔医学杂志, 2005, 21(3): 389-391.
[17] Chen D, Cheng J, Yang K, et al.Retrospective analysis of chronomodulated chemotherapy versus conventional chemotherapy with paclitaxel, carboplatin, and 5-fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma[J]. Onco Targets Ther, 2013, 6: 1507-1514.
[18] Ye H, Yang K, Tan XM, et al.Daily rhythm variations of the clock gene PER1 and cancer-related genes during various stages of carcinogenesis in a golden hamster model of buccal mucosa carcinoma[J]. Onco Targets Ther, 2015, 8: 1419-1426.
[19] Callaway E, Ledford H.Medicine Nobel awarded for work on circadian clocks[J]. Nature, 2017, 550(7674): 18.
[20] Zhang R, Lahens NF, Ballance HI, et al.A circadian gene expression atlas in mammals: implications for biology and medicine[J]. Proc Natl Acad Sci USA, 2014, 111(45): 16219-16224.
[21] 赵宁波, 杨凯, 唐洪, 等. 奥沙利铂对口腔鳞状细胞癌的时辰治疗[J]. 华西口腔医学杂志, 2013, 31(2): 131-135.
[22] Zhao N, Tang H, Yang K, et al.Circadian rhythm characteristics of oral squamous cell carcinoma growth in an orthotopic xenograft model[J]. Onco Targets Ther, 2013, 6: 41-46.
[23] Hori K, Zhang QH, Li HC, et al.Timing of cancer chemotherapy based on circadian variations in tumor tissue blood flow[J]. Int J Cancer, 1996, 65(3): 360-364.
[24] Blumenthal RD, Osorio L, Ochakovskaya R, et al.Regulation of tumour drug delivery by blood flow chronobiology[J]. Eur J Cancer, 2000, 36(14):1876-1884.
[25] 杨凯, 张福军, 李雅冬, 等. 时辰新辅助化疗治疗老年人口腔鳞癌的临床研究[J]. 中华老年口腔医学杂志, 2005, 3(1): 23-25.
[26] Tsuchiya Y, Ushijima K, Noguchi T, et al.Influence of a dosing-time on toxicities induced by docetaxel, cisplatin and 5-fluorouracil in patients with oral squamous cell carcinoma; a cross-over pilot study[J]. Chronobiol Int, 2018, 35(2): 289-294.
[27] Therasse P, Arbuck SG, Eisenhauer EA, et al.New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada[J]. J Natl Cancer Inst, 2000, 92(3): 205-216.
[28] Eisenhauer EA, Therasse P, Bogaerts J, et al.New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009, 45(2): 228-247.
[29] HHS, NIH, NCI. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 [DB/OL].2009. http://evs.nci.nih.gov/ftp1/CTCAE/About.html. |